Kimberly is the Chief Executive Officer at Zentalis Pharmaceuticals. Prior to joining Zentalis, she served as Chief Medical Officer and Senior Vice President, Oncology Clinical Development, at Tempus Labs. In this role, she oversaw precision medicine initiatives to improve cancer care and guide therapeutic drug development and discovery. Prior to joining Tempus, Kim was VP of Early Phase Oncology and Immunology-oncology at Eli Lilly and Company, where she worked on early stage cancer therapeutics. During her time at Lilly, she was named as one of “Twenty extraordinary women in biopharma R&D who worked their way to the top” by Endpoints News. For 18 years, Kim was a faculty member at the Duke University Cancer Institute. While at Duke, she served as the principal or co-principal investigator for over 50 cancer clinical trials, co-founded the radiotherapeutics company-Cereius, and co-directed the Woman’s Cancer Program and Precision Medicine Initiative. As one of the nation’s leading breast cancer researchers, she played a role in developing therapies that represent revolutionary non-chemotherapy-based approaches for treating cancer. This work led to Kim’s  inclusion in TIME Magazine’s 100 Most Influential People in the World for 2013, recognizing her accomplishments contributing to the development of lapatinib and T-DM1 for the treatment of HER2+ breast cancer. She holds a BA degree in Bioethics from Duke University and a MD degree from Mayo Clinic Medical School.

Cam is a cofounder and President at Zentalis Pharmaceuticals and has served as a member of the Board of Directors since the Company’s founding. He has 30 years of experience in the life sciences, with a focus on corporate development, marketing and company formation, and financing. In addition to Zentalis, Cam currently serves on the Board of Directors of Ocuphire, SelectION and Immusoft. He was also a founding Board member of VelosBio until its acquisition by Merck. From April 2016 to May 2022, he was the Chief Business Officer of Immusoft, a private company developing gene modified cell therapies for orphan diseases. Previously, Cam was a board member and Chief Business Officer at Retrosense Therapeutics, which was acquired by Allergan. He was also the Managing Director of Nerveda, LLC, a life science seed fund he co-founded in June 2007. Prior to these roles, he held leadership positions at Oncternal, Zavante, Verus Pharma, CV Therapeutics and Dura Pharma. Cam holds an MBA from the University of San Diego and a BS in Business Administration from Ohio University.

Interesting Fact: Cam attended the coldest game in NFL history, the Freezer Bowl (-59 degrees wind chill).

Kevin is a co-founder and Chief Scientific Officer at Zentalis Pharmaceuticals. Previously, he served as Chief Operating Officer and has been leading R&D at Zentalis since the Company’s formation. Prior to joining Zentalis, Kevin was a co-founder of Kalyra Pharmaceuticals and currently serves on the board of directors of Kalyra and as its Chief Scientific/Operations Officer. Prior, he was in Pfizer’s drug discovery research group in La Jolla as part of the Medicinal Chemistry Department. He specialized in multiple therapeutic areas including Oncology, Diabetes, Antivirals, and Ophthalmology. Prior to Pfizer, Kevin carried out postdoctoral research at The Scripps Research Institute under the direction of Professor Dale Boger. He received his PhD in Organic Chemistry from the University of California, San Diego under the direction of Joseph O’Connor and his BS in Chemistry from Arizona State University. Kevin is the inventor on multiple patents and an author of multiple articles in peer-reviewed journals.

Interesting Fact: Kevin sold precious metals from his late grandfather (Dr. Duane Brown) that were refined from eyeglass frames, circuit boards, and dental scraps to help kick-off Kalyra.

Carrie Brownstein, M.D. joined Zentalis in October 2022 as Chief Medical Officer.  Prior to joining Zentalis, Dr. Brownstein served as the Chief Medical Officer of Cellectis, where she built and led the global clinical development organization and oversaw multiple early-stage clinical programs in the cell therapy space. Previously, she held roles of increasing responsibility at Celgene, culminating in the role of VP of Global Clinical Research and Development. During her tenure at Celgene, Dr. Brownstein managed a team of physicians and scientists across multiple global sites and was responsible for the development strategy and clinical execution of several late-stage assets, resulting in the approval of four novel products in myeloid diseases. Prior to Celgene, she served as the Executive Director of Clinical Sciences, Oncology at Regeneron Pharmaceuticals and implemented first-in-human studies for various malignant hematology and oncology indications including bispecific T-cell engagers in lymphoma. Dr. Brownstein started her industry career at Hoffmann-La Roche, as a Senior Medical Director, where her accomplishments were highlighted by the EMA approval of Xeloda in adjuvant colon cancer. She currently serves as a member of the Board of Directors of Shattuck Labs. Prior to her career in industry, Dr. Brownstein practiced medicine as a pediatric oncologist within notable institutions, including New York Presbyterian Columbia University, Memorial Sloan Kettering Cancer Center and Mount Sinai Medical Center. She received her BA from the University of Michigan and her MD from Tufts University School of Medicine.

Melissa is Chief Financial Officer at Zentalis Pharmaceuticals. She brings extensive experience as a senior financial executive in the life sciences industry. She most recently served as CFO at PsiOxus Therapeutics, a clinical-stage gene therapy cancer company, and prior to that, CFO and Head of Business Development at R-Pharm US, a commercial-stage oncology company. Previously, Melissa was a Director at Anchorage Capital Group, a credit-focused hedge fund; a Vice President at Goldman Sachs in equity research in New York and London where she built GS SUSTAIN; and a management consultant with Bain & Company focused on international and US based pharmaceutical clients and private equity. She began her career at Morgan Stanley in New York in healthcare investment banking. Melissa earned her MBA from Harvard Business School and BA in Biochemistry and Economics from the University of Virginia, where she graduated Phi Beta Kappa.

Interesting Fact: Melissa logged six hours towards her pilot’s license and twice attended NASA’s Space Camp before the age of 12.

Mark is Chief Translational Officer and Head of Biomarker Strategy. He has over 20 years of experience in oncology drug development with broad experience ranging from target identification through biomarker development in registrational clinical trials. Prior to joining Zentalis, Mark served as SVP and Head of Biology and Translational Sciences at Ideaya Biosciences from 2018 to October 2022. At Ideaya Mark’s group led clinical translational efforts for the PKC inhibitor darovasertib and the MAT2A inhibitor IDE397 and contributed to three development candidate nominations and one IND. Prior to joining IDEAYA, Mark worked at Genentech for 14 years in positions of increasing responsibility in the Oncology Biomarker Development group, most recently as a Director and Principal Scientist. At Genentech his group was accountable for predictive and pharmacodynamic strategies for candidate therapeutics spanning cancer signaling through immuno-oncology, and was accountable for clinical biomarker strategies for over 20 development stage small molecule and antibody agents. His group developed clinical biomarker strategies for immune doublet combinations with the anti-PDL1 antibody Tecentriq, as well as phase III companion diagnostic strategies for the AKT inhibitor Ipatasertib and the MEK and BRAF inhibitors Cobimetinib and Vemurafenib. Mark also provided strategic leadership for the overall breast cancer biomarker strategy within the broader Roche organization. Prior to joining Genentech, Mark worked at Exelixis from 1999 through 2004 in oncology target identification and validation, including the identification of synthetic lethal interactions with the tumor suppressor gene p53. Mark received his PhD from Stanford University in 1997 for studies on genetic analysis of RAS/MAP kinase signaling. He completed postdoctoral studies at UC Berkeley in the laboratory of Joshua Kaplan. He has authored over 60 peer reviewed scientific manuscripts in journals including Nature Medicine, Nature Communications, Journal of Clinical Oncology, Cancer Cell and Clinical Cancer Research.

Interesting Fact: Mark is an avid hiker and has backpacked over 2000 miles through California's High Sierra mountains.

Kimberly is Chief Strategy Officer at Zentalis Pharmaceuticals. Prior to joining Zentalis, Kimberly was Vice President, US Head of DDR Franchise, Oncology at AstraZeneca. She was responsible for overseeing the strategic direction and cross-functional efforts for LYNPARZA® (olaparib) and other therapies targeting the DDR pathway, which is an important hallmark in ovarian and other cancers. Previously, she held various leadership roles at biopharmaceutical companies including Adaptimmune, Boehringer Ingelheim and GlaxoSmithKline. Kimberly has also served on the Alliance for Regenerative Medicine (ARM) Cell Therapy Advisory Committee and has been recognized by Women in Bio as a Female Pioneer in the Life Sciences. After receiving her Bachelor of Science in Biology from Cornell University, she was a Research Scientist in the Department of Hematology/Medical Oncology at Weill Cornell Medical Center and later pursued Microbiology Graduate Studies at SUNY Upstate Medical Center. Kimberly also received Finance and Marketing Certificates from the Wharton School of the University of Pennsylvania.

Interesting Fact: Kimberly is an avid runner, having completed 5 marathons including New York and Boston!

Andrea Paul joined Zentalis in August 2022 as General Counsel and Corporate Secretary. Previously, Ms. Paul served as General Counsel and Corporate Secretary of LogicBio Therapeutics, Inc., where she led the company’s legal team and served as a key strategic legal partner in the company’s finance, business development and contractual decision-making matters. Before that, she held positions of increasing responsibility at Akebia Therapeutics, Inc., culminating in the role of Vice President, Legal. While at Akebia, Ms. Paul was a key strategic legal partner in the company’s merger with Keryx Biopharmaceuticals, Inc. as well as in the company’s financing and business development transactions. Prior to Akebia, she served as Senior Corporate Counsel at Momenta Pharmaceuticals, Inc. She began her legal career working as an associate at Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. and Sullivan and Cromwell LLP. Ms. Paul currently chairs the Securities Law Committee of the Boston Bar Association. She received her J.D. from Harvard Law School and her B.A. in Art History from Columbia University.

Interesting Fact: Andrea is a dedicated Michael Schumacher fan and still watches replays of his F1 races.